This Article Full Text Full Text (PDF) CME: Take the course for this article: Chromogenic In Situ Hybridization to Detect HER-2/neu Gene Amplifica... eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vocaturo, A. Articles by Mottolese, M. Search for Related Content PubMed PubMed Citation Articles by Vocaturo, A. Articles by Mottolese, M.

Cancer Diagnostics and Molecular Pathology

Chromogenic In Situ Hybridization to Detect HER-2/neu Gene Amplification in Histological and ThinPrep^®-Processed Breast Cancer Fine-Needle Aspirates: A Sensitive and Practical Method in the Trastuzumab Era

^a Pathology Department, ^b Clinical Pathology, ^c Biostatistics Unit, ^d Breast Disease Management Team, Regina Elena Cancer Institute, Rome, Italy

Key Words. Breast cancer • HER-2 • Chromogenic in situ hybridization • Fluorescence in situ hybridization • Liquid-based cytology

Correspondence: Amina Vocaturo, Ph.D., Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy. Telephone: 390652666905; Fax: 390652666139; e-mail: vocaturo{at}ifo.it

The increasing evidence of trastuzumab efficacy in breast cancer (BC) patients means that an accurate and reproducible evaluation of HER-2 statusis of paramount importance in histological and in cytological samples. Currently, the two main methods used to analyze HER-2 amplification or overexpression are fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Although the two methods are strongly correlated for histological tissue, the evaluation of tumor morphology through FISH may be difficult and fluorescence fades quickly. These limitations can be overcome by chromogenic in situ hybridization (CISH), which can visualize the amplification product along with morphological features. In view of this, in the present study, we analyzed the usefulness of CISH on formalin-fixed, paraffin-embedded (FFPE) BC specimens and investigated whether CISH can be a valid technique in the determination of HER-2 status for fine-needle aspirates (FNAs) processed by liquid-based cytology. The results we obtained in a retrospective series of 111 FFPE BC specimens demonstrated good concordance between CISH and IHC and between CISH and FISH. The former concordance was comparable with that observed between FISH and IHC. When CISH was applied to a prospective series of 53 FNAs, from surgically removed BC, our data showed evidence of a higher concordance of results between liquid-based cytology and the companion FFPE tissues using CISH rather than HercepTest^TM. Therefore, CISH analysis, which is avaluable and reproducible alternative to FISH for selecting breast cancer patients for trastuzumab therapy, can lower false-positive immunocytochemistry findings in ThinPrep^®-processed FNAs.

This article has been cited by other articles:

				S Di Palma, N Collins, M Bilous, A Sapino, M Mottolese, N Kapranos, F Schmitt, and J Isola A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer J. Clin. Pathol., June 1, 2008; 61(6): 757 - 760. [Abstract] [Full Text] [PDF]

				F C Schmitt, A Longatto-Filho, A Valent, and P Vielh Molecular techniques in cytopathology practice J. Clin. Pathol., March 1, 2008; 61(3): 258 - 267. [Abstract] [Full Text] [PDF]

				S. A. V. Ricardo, F. Milanezi, S. T. Carvalho, D. R. A. Leitao, and F. C. L. Schmitt HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas J. Clin. Pathol., September 1, 2007; 60(9): 1001 - 1005. [Abstract] [Full Text] [PDF]